Key result
Mean eGFR is not linked to serious bleeding events in patients treated with coumarins.
Why the study?
Does renal impairment increase the risk of serious bleeding events in patients treated with coumarins?
Case-Control (n=6,622)
Does renal impairment increase the risk of serious bleeding events in patients treated with coumarins?
Renal function (eGFR) in the preceding year is not associated with an increased risk of serious bleeding events requiring hospitalization in patients treated with coumarins.
Answers are grounded in this paper and cite their sources.
Renal function showed no association with coumarin-related bleeding; this Level 4 analysis leaves open whether eGFR monitoring should guide therapy.
Background: Although anticoagulation therapy is closely monitored in the Netherlands, coumarin-induced serious bleeding events are still observed. Current literature suggests that renal impairment may contribute to this. Objective: To explore the association between renal function and bleeding events during coumarin treatment. Methods: A nested case-control study was conducted using data from the PHARMO Database Network. Patients hospitalized for a bleeding event during coumarin treatment were selected as cases and matched on sex, birth year, and geographic region to up to 2 controls using coumarins without hospitalization for bleeding. All values of estimated glomerular filtration rates (eGFRs) were selected in the year before index date (case hospitalization date) and compared between cases and controls using logistic regression analyses. Results: In total, 2224 cases were matched to 4398 controls (61% male; mean ± SD age 75 ± 11 and 78 ± 11 years among cases and controls, respectively). Availability of eGFR values was higher among cases compared with controls (mean ± SD eGFR values 4.5 ± 7.1 vs 3.2 ± 5.5), reflected in the significantly shorter time since last eGFR value (at index date, mean ± SD = 2.7 ± 3.0 vs 3.8 ± 3.1 months; odds ratio [OR] = 0.91, 95%CI = 0.89-0.92). No statistically significant difference was found for the mean eGFR value in the year before index date (mean ± SD 65.7 ± 22.8 vs 64.6 ± 20.9 mL/min/1.73 m 2 ; OR per 10 units [95%CI] = 0.99 [0.96-1.02]). Conclusions: No association between renal function and serious bleeding events during coumarin treatment was observed.
No takes yet. Share an insight, caveat, or question.
Houben et al. (2017) conducted a case-control in Coumarin-induced serious bleeding events (n=6,622). Renal function (eGFR) was evaluated on Hospitalization for a bleeding event (OR 0.99, 95% CI 0.96-1.02). Renal function (mean eGFR in the prior year) was not associated with serious bleeding events in patients treated with coumarins.
Synapse has enriched 10 related papers. Consider them for comparative context: